Retatrutide dosage: what the published trials have studied.

Plain English: what this page is and isn't

Retatrutide is an investigational drug — it has no approved dosage, no FDA label, and no medical prescription pathway as of 2026. This page describes the doses that were studied in clinical trials, the half-life that was measured in the first human studies, the routes used, and the escalation designs the trials employed. This is factual reporting on trial protocols.

This page is not a dosing guide. It does not contain recommendations about how much to use, when to inject, or how to escalate. Those questions are unanswerable outside a clinical trial with medical supervision. Anyone asking because they have obtained gray-market retatrutide should understand: the product they have may not be retatrutide, it has no verified purity, it is not sterile-certified, and there is no clinical oversight available outside a trial. The safety cautions on the effects page are directly relevant.

Retatrutide dosage in the published trials

Phase 1b (first-in-human): doses of 0.5, 1.5, 3, 3/6, and 3/6/9/12 mg once weekly, administered by subcutaneous injection to 72 adults with type 2 diabetes over 12 weeks ^[4]. The highest group escalated through 3, 6, 9, and 12 mg in stepwise fashion. Placebo-adjusted weight loss at the highest dose: -8.96 kg over 12 weeks.

Phase 2 obesity trial (48 weeks): fixed doses of 1, 4, 8, or 12 mg once weekly administered by subcutaneous injection after escalation ^[1]. The escalation design — gradually increasing doses over the first weeks — was used in all Phase 2 arms to limit GI adverse events. At the 12 mg final dose, mean body-weight change was -24.2% vs -2.1% placebo.

Phase 2 type 2 diabetes trial (36 weeks): stepwise escalation starting at 0.5 mg up to 12 mg once weekly, subcutaneous ^[2]. HbA1c reduction -2.02% and body-weight reduction -16.94% at the highest dose by 36 weeks.

All trial doses were once-weekly subcutaneous injections. No oral or intravenous formulation was studied in any published Phase 2 data.

Retatrutide half life

The Phase 1b trial characterized retatrutide pharmacokinetics in humans: half-life approximately 6 days ^[4]. A 6-day half-life means it takes about 6 days for blood concentration to fall by half after a given dose, and approximately 4-5 half-lives (24-30 days) to clear the compound substantially from the bloodstream after stopping. This is the pharmacokinetic basis for the once-weekly dosing used in all Phase 2 and Phase 3 studies.

Practically, the ~6-day half-life also means that if adverse effects occur — particularly the GI events or heart-rate elevations documented in Phase 2 — they persist on a multi-day timeline rather than resolving within hours. Phase 2 participants were in monitored clinical settings with medical oversight available throughout. The 2025 Biomolecules review ^[6] notes that the pharmacokinetic profile supporting weekly dosing is one of the compound's key engineering design features, achieved through the C20 fatty-diacid acylation that extends albumin binding (the molecule is attached to a fatty-acid chain that lets it hitch a ride on blood proteins, dramatically slowing its clearance).

Is retatrutide fda approved

No. As of 2026, retatrutide is not approved by the FDA, the EMA, or any other regulatory authority. It has not completed Phase 3 trials and no regulatory submission has been made. The TRIUMPH Phase 3 program (obesity, type 2 diabetes, cardiovascular outcomes, CKD) is ongoing. Eli Lilly has not announced a target submission date.

Approval requires Phase 3 trial completion, a full regulatory dossier, and a FDA review period that typically runs 6-12 months after filing. Even if Phase 3 completes on schedule, approval would be no earlier than 2027 at the earliest, and is not guaranteed. Most investigational drugs fail to reach approval; Phase 2 results, however promising, are not Phase 3 results.

When will retatrutide be available

No approved version of retatrutide is available anywhere, and no projected approval date has been announced as of 2026. The TRIUMPH Phase 3 trials are ongoing. Enrollment completed for several arms in 2024-2025; primary completion dates vary by trial from late 2025 through 2027. A regulatory submission, review, and approval process would follow data completion and analysis. The timeline is in Eli Lilly's hands and is subject to trial outcomes, FDA review, and regulatory events that cannot be predicted.

Gray-market research-labeled retatrutide is available through peptide research vendors, but that material is not the approved product — it is unregulated, unverified, and outside any clinical oversight structure. This site does not facilitate access to that market.

How to reconstitute retatrutide

Reconstitution — dissolving a lyophilized (freeze-dried) powder in a solvent before injection — is a standard procedure for many research peptides. However, this site does not provide reconstitution instructions for retatrutide.

The reason is straightforward: retatrutide is an investigational drug studied only as a clinical-trial investigational product administered under medical supervision. No approved formulation, storage requirement, or reconstitution standard exists for any non-trial preparation. Gray-market retatrutide powder has no verified identity or purity, and reconstituting it with unverified technique for self-injection combines multiple independent risk factors: unknown compound concentration, potential contamination, and no sterility assurance.

Clinical trials administer the compound in manufacturer-prepared, quality-controlled formulations under nursing and physician oversight. That is the only context in which reconstitution and administration have been studied.

Retatrutide availability — route and formulation details

All published Phase 1 and Phase 2 data used subcutaneous injection — injection into the fatty layer beneath the skin — as the only route. No intravenous, oral, or intranasal formulations have been reported in any published human study. The once-weekly schedule and subcutaneous route are consistent with the ~6-day half-life and with the broader trend toward extended-release subcutaneous peptide formulations in the incretin class.

The compound's structure — a 39-amino-acid peptide with a C20 fatty-diacid modification for albumin binding — means oral bioavailability would be negligibly low without specialized oral formulation technology. Lilly has not announced any oral formulation program for retatrutide, in contrast to the oral semaglutide program for that compound.